Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.42 |
| ▸ | AURKA | O14965 | 18/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 9/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | PLK4 | O00444 | 1/20 | 0.39 |
| ▸ | PAK4 | O96013 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13054529 | 0.89 | AURKA (0.42) | PIK3C3AURKAAURKB | |
| SCHEMBL13054526 | 0.88 | DOT1L (0.51) | PIK3C3AURKAAURKBSRCGSK3B | |
| SCHEMBL13054516 | 0.82 | AURKA (0.49) | PIK3C3AURKAAURKBSRCGSK3B | |
| SCHEMBL13840507 | 0.81 | AURKA (0.49) | PIK3C3AURKAAURKBSRCGSK3B | |
| SCHEMBL13054870 | 0.80 | AURKA (0.36) | AURKAAURKBGSK3BPLK4PAK4 | |
| SCHEMBL13054528 | 0.80 | AURKA (0.47) | PIK3C3AURKAAURKBSRCGSK3B | |
| SCHEMBL12430939 | 0.79 | AURKA (0.61) | PIK3C3AURKAAURKBSRCGSK3B | |
| SCHEMBL13054518 | 0.78 | AURKA (0.45) | PIK3C3AURKAAURKBSRC | |
| SCHEMBL13081379 | 0.77 | AURKA (0.41) | PIK3C3AURKAAURKBSRCGSK3B | |
| SCHEMBL13054452 | 0.77 | AURKA (0.70) | AURKAAURKBSRCGSK3BPLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7842712-B2 | Indazolinone compositions useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-11-30 | — | — | US | disclosed |
| US-7842712-B2 | Indazolinone compositions useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-11-30 | — | — | US | disclosed |
| US-20090048250-A1 | INDAZOLINONE COMPOSITIONS USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-02-19 | — | — | US | disclosed |
| US-20090048250-A1 | INDAZOLINONE COMPOSITIONS USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-02-19 | — | — | US | disclosed |
| US-7262200-B2 | Indazolinone compositions useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-08-28 | — | — | US | disclosed |
| US-7262200-B2 | Indazolinone compositions useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048250-A1 | INDAZOLINONE COMPOSITIONS USEFUL AS KINASE INHIBITORS | LCK, CDK2, MKNK2 | PIK3C3 220/4885AURKA 10/4885AURKB 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.